Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics

Abstract Objectives This study aims to develop and validate a novel radiomics model utilizing magnetic resonance imaging (MRI) to predict progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) who are receiving a combination of immune checkpoint inhibitors (ICI...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuni Xu, Xue Jiang, Haoran Jiang, Xiaoye Yuan, Mengjing Zhao, Yuqi Wang, Gang Chen, Gang Li, Yuxia Duan
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-14247-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849325894844284928
author Xuni Xu
Xue Jiang
Haoran Jiang
Xiaoye Yuan
Mengjing Zhao
Yuqi Wang
Gang Chen
Gang Li
Yuxia Duan
author_facet Xuni Xu
Xue Jiang
Haoran Jiang
Xiaoye Yuan
Mengjing Zhao
Yuqi Wang
Gang Chen
Gang Li
Yuxia Duan
author_sort Xuni Xu
collection DOAJ
description Abstract Objectives This study aims to develop and validate a novel radiomics model utilizing magnetic resonance imaging (MRI) to predict progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) who are receiving a combination of immune checkpoint inhibitors (ICIs) and antiangiogenic agents. This is an area that has not been previously explored using MRI-based radiomics. Methods 111 patients with uHCC were enrolled in this study. After performing univariate cox regression and the least absolute shrinkage and selection operator (LASSO) algorithms to extract radiological features, the Rad-score was calculated through a Cox proportional hazards regression model and a random survival forest (RSF) model. The optimal calculation method was selected by comparing the Harrell’s concordance index (C-index) values. The Rad-score was then combined with independent clinical risk factors to create a nomogram. C-index, time-dependent receiver operating characteristics (ROC) curves, calibration curves, and decision curve analysis were employed to assess the forecast ability of the risk models. Results The combined nomogram incorporated independent clinical factors and Rad-score calculated by RSF demonstrated better prognosis prediction for PFS, with C-index of 0.846, 0.845, separately in the training and the validation cohorts. This indicates that our model performs well and has the potential to enable more precise patient stratification and personalized treatment strategies. Based on the risk level, the participants were classified into two distinct groups: the high-risk signature (HRS) group and the low-risk signature (LRS) group, with a significant difference between the groups (P < 0.01). Conclusion The effective clinical-radiomics nomogram based on MRI imaging is a promising tool in predicting the prognosis in uHCC patients receiving ICIs combined with anti-angiogenic agents, potentially leading to more effective clinical outcomes.
format Article
id doaj-art-502cdbd18d5f42dc9fd0e87b0d7c29b3
institution Kabale University
issn 1471-2407
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-502cdbd18d5f42dc9fd0e87b0d7c29b32025-08-20T03:48:18ZengBMCBMC Cancer1471-24072025-05-0125111810.1186/s12885-025-14247-0Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomicsXuni Xu0Xue Jiang1Haoran Jiang2Xiaoye Yuan3Mengjing Zhao4Yuqi Wang5Gang Chen6Gang Li7Yuxia Duan8Department of Radiology, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing UniversityDepartment of Pathology, Jinhua Municipal Central Hospital, Affiliated Jinhua Hospital, Zhejiang University School of MedicineDepartment of Radiation and Chemotherapy Oncology, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Radiation and Chemotherapy Oncology, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Radiation and Chemotherapy Oncology, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Radiation and Chemotherapy Oncology, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical UniversityAbstract Objectives This study aims to develop and validate a novel radiomics model utilizing magnetic resonance imaging (MRI) to predict progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) who are receiving a combination of immune checkpoint inhibitors (ICIs) and antiangiogenic agents. This is an area that has not been previously explored using MRI-based radiomics. Methods 111 patients with uHCC were enrolled in this study. After performing univariate cox regression and the least absolute shrinkage and selection operator (LASSO) algorithms to extract radiological features, the Rad-score was calculated through a Cox proportional hazards regression model and a random survival forest (RSF) model. The optimal calculation method was selected by comparing the Harrell’s concordance index (C-index) values. The Rad-score was then combined with independent clinical risk factors to create a nomogram. C-index, time-dependent receiver operating characteristics (ROC) curves, calibration curves, and decision curve analysis were employed to assess the forecast ability of the risk models. Results The combined nomogram incorporated independent clinical factors and Rad-score calculated by RSF demonstrated better prognosis prediction for PFS, with C-index of 0.846, 0.845, separately in the training and the validation cohorts. This indicates that our model performs well and has the potential to enable more precise patient stratification and personalized treatment strategies. Based on the risk level, the participants were classified into two distinct groups: the high-risk signature (HRS) group and the low-risk signature (LRS) group, with a significant difference between the groups (P < 0.01). Conclusion The effective clinical-radiomics nomogram based on MRI imaging is a promising tool in predicting the prognosis in uHCC patients receiving ICIs combined with anti-angiogenic agents, potentially leading to more effective clinical outcomes.https://doi.org/10.1186/s12885-025-14247-0Hepatocellular carcinomaRadiomicsProgression‑free survivalImmune checkpoint inhibitorsAnti-angiogenic agents
spellingShingle Xuni Xu
Xue Jiang
Haoran Jiang
Xiaoye Yuan
Mengjing Zhao
Yuqi Wang
Gang Chen
Gang Li
Yuxia Duan
Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
BMC Cancer
Hepatocellular carcinoma
Radiomics
Progression‑free survival
Immune checkpoint inhibitors
Anti-angiogenic agents
title Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
title_full Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
title_fullStr Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
title_full_unstemmed Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
title_short Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
title_sort prediction of prognosis of immune checkpoint inhibitors combined with anti angiogenic agents for unresectable hepatocellular carcinoma by machine learning based radiomics
topic Hepatocellular carcinoma
Radiomics
Progression‑free survival
Immune checkpoint inhibitors
Anti-angiogenic agents
url https://doi.org/10.1186/s12885-025-14247-0
work_keys_str_mv AT xunixu predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT xuejiang predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT haoranjiang predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT xiaoyeyuan predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT mengjingzhao predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT yuqiwang predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT gangchen predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT gangli predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics
AT yuxiaduan predictionofprognosisofimmunecheckpointinhibitorscombinedwithantiangiogenicagentsforunresectablehepatocellularcarcinomabymachinelearningbasedradiomics